The survival rate for people with lung cancer is improving, according to the new State of Lung Cancer report. The American Lung Association report says there have been important advances in early ...

More than 17,000 individuals with cancer died from their malignancy within a year of their diagnosis during the COVID-19 pandemic than expected based on previous trends.An evaluation of 1-year ...

Pulmonologist Dr. Katie Capp warns her patients that cigarette smoke is the leading cause of preventable death worldwide, but ...

A new study is shining a light on a potential way to make treatments work better for one of the deadliest forms of cancer. Researchers at Ohio University have identified a protein that could be a ...

Modelling indicates that over a 20-year period, a national screening programme could detect around 9,000 lung cancers and potentially save more than 6,000 lives – an estimated 300 lives each year.

Multidisciplinary evaluation, including thoracic surgical consultation, is crucial for oligometastatic NSCLC patients to optimize treatment strategies. Lung surgery for oligometastatic NSCLC shows ...

CULVER CITY, Calif.--(BUSINESS WIRE)--Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), today announced positive results from its QUILT 3.055 trial demonstrating long-term extended survival of ...

An international team confirms in a pioneering phase 3 clinical trial the decisive role of the time of day on the success of anti-tumour immunotherapies.

Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients with lung cancer who received an immunotherapy drug, nivolumab, along with ...

Researchers have shown that a test called ORACLE can predict lung cancer survival at the point of diagnosis better than currently used clinical risk factors. This could help doctors make more informed ...

Please provide your email address to receive an email when new articles are posted on . TNF inhibitors within 3 years of diagnosis had no statistically significant negative link with colorectal, lung ...

AstraZeneca (NASDAQ:AZN) announced Friday that its anti-PD-L1 immunotherapy Imfinzi as a late-line option significantly improved patients' survival in a global late-stage trial for small cell lung ...